Publications

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

 135
GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Tags:

Previous Article

Oncogene mutation in colorectal cancer leads to metabolic reprogramming

Next Article

GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity

Related Posts

Bidirectional histone monoaminylation dynamics regulate neural rhythmicity

Bidirectional histone monoaminylation dynamics regulate...

 121

Deep immune profiling delineates hallmarks of disease heterogeneity in extrapulmonary tuberculosis

Deep immune profiling delineates hallmarks of disease h...

 53

Heterogeneity in the coordination of delta cells with beta cells is driven by both paracrine signals and low-density Cx36 gap junctions

Heterogeneity in the coordination of delta cells with b...

 71